Yahoo
Milan - Delayed Quote EUR

DiaSorin S.p.A. (DIA.MI)

80.56 -0.04 (-0.05%)
At close: October 30 at 5:35:13 PM GMT+1
Chart Range Bar
Loading chart for DIA.MI
  • Previous Close 80.60
  • Open 81.04
  • Bid 80.38 x --
  • Ask 80.42 x --
  • Day's Range 80.00 - 81.28
  • 52 Week Range 52.34 - 82.30
  • Volume 92,271
  • Avg. Volume 177,109
  • Market Cap (intraday) 3.969B
  • Beta (5Y Monthly) 0.67
  • PE Ratio (TTM) 29.62
  • EPS (TTM) 2.72
  • Earnings Date (est.) Nov 5, 2026
  • Forward Dividend & Yield 1.30 (1.61%)
  • Ex-Dividend Date May 18, 2026
  • 1y Target Est 76.38

DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. In addition, it offers LIAISON PLEX Respiratory Flex Assay and the LIAISON PLEX Yeast Blood Culture Assay. Further, the company offers xMAP technology platform, including in vitro diagnostics. The company was founded in 1968 and is headquartered in Saluggia, Italy.

int.diasorin.com

3,260

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is FTSE MIB Index (FTSEMIB.MI) .

YTD Return

DIA.MI
19.61%
FTSE MIB Index (FTSEMIB.MI)
10.14%

1-Year Return

DIA.MI
7.54%
FTSE MIB Index (FTSEMIB.MI)
14.58%

3-Year Return

DIA.MI
2.42%
FTSE MIB Index (FTSEMIB.MI)
81.06%

5-Year Return

DIA.MI
56.11%
FTSE MIB Index (FTSEMIB.MI)
84.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 315M
Earnings 46M
Profit Margin 14.60%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
100M
200M
300M
6.0%
8.0%
10.0%
12.0%
14.0%

Analyst Insights

View More

Analyst Price Targets

55.00 Low
76.38 Average
80.56 Current
95.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    11.94%

  • Return on Assets (ttm)

    5.52%

  • Return on Equity (ttm)

    9.16%

  • Revenue (ttm)

    1.18B

  • Net Income Avi to Common (ttm)

    140.57M

  • Diluted EPS (ttm)

    2.72

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    120.88M

  • Total Debt/Equity (mrq)

    68.18%

  • Levered Free Cash Flow (ttm)

    132.73M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: